Aytu BioPharma (NASDAQ:AYTU) Stock Crosses Below Fifty Day Moving Average – Time to Sell?

Shares of Aytu BioPharma Inc. (NASDAQ:AYTU) passed below its 50 day moving average during trading on Thursday. The stock has a 50 day moving average of $2.15 and traded as low as $1.96. Aytu BioPharma shares last traded at $1.98, with a volume of 25,716 shares.

Analyst Upgrades and Downgrades

Several research analysts have weighed in on AYTU shares. Weiss Ratings lowered shares of Aytu BioPharma from a “sell (d)” rating to a “sell (d-)” rating in a research report on Tuesday, October 6th. Citigroup reaffirmed a “positive” rating on shares of Aytu BioPharma in a report on Tuesday, September 22nd. Finally, Zacks Research downgraded shares of Aytu BioPharma from a “hold” rating to a “strong sell” rating in a research report on Monday, October 5th. Two equities research analysts have rated the stock with a Buy rating and two have given a Sell rating to the company. According to data from MarketBeat, Aytu BioPharma currently has an average rating of “Hold” and an average price target of $14.50.

Aytu BioPharma Price Performance

The company has a market cap of $20.65 million, a price-to-earnings ratio of -1.14 and a beta of 0.17. The company has a fifty day simple moving average of $2.14 and a two-hundred day simple moving average of $2.24. The company has a quick ratio of 1.00, a current ratio of 1.13 and a debt-to-equity ratio of 0.26.

Hedge Funds Weigh In On Aytu BioPharma

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in AYTU. Nantahala Capital Management LLC acquired a new stake in shares of Aytu BioPharma in the second quarter valued at approximately $2,336,646. Stonepine Capital Management LLC purchased a new position in shares of Aytu BioPharma during the 2nd quarter worth approximately $1,962,780. AWM Investment Company Inc. acquired a new position in shares of Aytu BioPharma during the 2nd quarter worth approximately $1,332,000. Crown Advisors Management Inc. acquired a new position in shares of Aytu BioPharma during the 2nd quarter worth approximately $430,000. Finally, Arete Wealth Advisors LLC acquired a new position in shares of Aytu BioPharma during the 1st quarter worth approximately $135,000. Institutional investors and hedge funds own 33.49% of the company’s stock.

Aytu BioPharma Company Profile

Aytu BioPharma, Inc is a specialty pharmaceutical company focused on developing and commercializing prescription medicines for pediatric and primary-care markets. The company’s portfolio includes treatments for attention-deficit/hyperactivity disorder (ADHD), along with products addressing allergies, respiratory conditions, and other common health needs.

Aytu’s ADHD portfolio has included orally disintegrating and liquid formulations designed for children and adolescents, such as Adzenys XR-ODT, Cotempla XR-ODT, and Dyanavel XR.